Skip to main content

Table 3 Quality measures for patients diagnosed with CRC between 2004 and 2006, and comparisons by geography

From: Does geography influence the treatment and outcomes of colorectal cancer? A population-based analysis

  

Geographic variation

RHA group

Quality measure

Overall (n/N)

Winnipeg (n/N)

Other (n/N)

P value

Winnipeg

North Manitoba

South Manitoba

Middle Manitoba

P value

 

(n/ N)

(n/ N)

(n/ N)

(n/ N)

 

Total colonic examination

75.55%

75.08%

76.20%

0.604

75.08%

65.00%

74.00%

81.53%

0.049

(1,230/1,628)

(705/939)

(525/689)

(705/939)

(26/40)

(296/400)

(203/249)

Anastomotic leak/reoperation rate

1.72%

2.17%

1.13%

0.168

2.17%

2.94%

1.34%

0.51%

0.355a

(21/1,220)

(15/691)

(6/529)

(15/691)

(1/34)

(4/298)

(1/197)

Extent of lymphadenectomy

         

>12 lymph nodes

68.75%

69.07%

68.31%

0.749

69.07%

58.97%

72.42%

63.22%

0.054

(1,080/1,571)

(623/902)

(457/669)

(623/902)

(23/39)

(281/388)

 

Positive lymph node status

45.47%

45.76%

45.09%

0.790

45.76%

48.72%

43.48%

47.11%

0.781

(719/1,581)

(416/909)

(303/672)

(416/909)

(19/39)

(170/391)

(114/242)

Medical oncology for rectal cancer

         

Stage I to IV preoperative consultation

13.15%

12.90%

13.51%

0.866

12.90%

28.57%

13.51%

11.94%

0.668

(48/365)

(28/217)

(20/148)

(28/217)

(2/7)

(10/74)

(8/67)

Stage II/III preoperative consultation

16.25%

14.48%

18.95%

0.359

14.48%

40.00%

22.73%

13.04%

0.250

(39/240)

(21/145)

(18/95)

(21/145)

(2/5)

(10/44)

(6/46)

Stage II/III seen within 8 weeks of major surgery

36.25%

37.24%

34.74%

0.693

37.24%

40.00%

43.18%

26.09%

0.382

(87/240)

(54/145)

(33/95)

(54/145)

(2/5)

(19/44)

(12/46)

Stage II/III seen within 16 weeks of major surgery

63.33%

63.45%

63.16%

0.964

63.45%

60.00%

77.27%

50.00%

0.065

(152/240)

(92/145)

(60/95)

(92/145)

(3/5)

(34/44)

(23/46)

Radiation oncology for rectal cancer

         

Stage I to IV preoperative consultation

17.81%

18.43%

16.89%

0.706

18.43%

14.29%

18.92%

14.93%

0.906

(65/365)

(40/217)

(25/148)

(40/217)

(1/7)

(14/74)

(10/67)

Stage II/III preoperative consultation

22.50%

23.45%

21.05%

0.664

23.45%

20.00%

27.27%

15.22%

0.559

(54/240)

(34/145)

(20/95)

(34/145)

(1/5)

(12/44)

(7/46)

Stage II/III seen within 8 weeks of major surgery

31.25%

33.79%

27.37%

0.294

33.79%

0%

27.27%

30.43%

0.384

(75/240)

(49/145)

(26/95)

(49/145)

(0/5)

(12/44)

(14/46)

Stage II/III seen within 16 weeks of major surgery

67.08%

68.28%

65.26%

0.627

68.28%

40.0%

77.27%

56.52%

0.105

(161/240)

(99/145)

(62/95)

(99/145)

(2/5)

(34/44)

(26/46)

Stage III colon cancer seen within 8 weeks of surgery

27.27%

27.35%

27.15%

0.966

27.35%

55.56%

28.92%

20.34%

0.160

(102/374)

(61/223)

(41/151)

(61/223)

(5/9)

(24/83)

(12/59)

Stage III colon cancer seen within 16 weeks of surgery

50.80%

47.09%

56.29%

0.081

47.09%

77.78%

63.86%

42.37%

0.011

(190/374)

(105/223)

(85/151)

(105/223)

(7/9)

(53/83)

(25/59)

30-day mortality

3.75%

4.05%

3.34%

0.506^

4.05%

2.5%

4.00%

2.41%

0.643^

(61/1,628)

(38/939)

(23/689)

(38/939)

(1/40)

(16/400)

(6/249)

Surveillance colonoscopy within 12 months of surgery

29.62%

30.06%

29.02%

0.674

30.06%

25.00%

31.33%

26.05%

0.535

(410/1,384)

(242/805)

(168/579)

(242/805)

(8/32)

(104/332)

(56/215)

Surveillance colonoscopy within 14 months of surgery

45.37%

47.22%

42.81%

0.106

47.22%

32.26%

45.12%

40.76%

0.167

 

(618/1,362)

(374/792)

(244/570)

 

(374/792)

(10/31)

(148/328)

(86/211)

 
  1. aUsage of Monte-Carlo estimation of exact P value instead of direct P value computations, since the sample size is large and some cell values are less than five; ^death within 30 days compared to death after 30 days and patients who were still alive. CRC colorectal cancer, RHA regional health authority.